Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Effects of electroacupuncture and fluoxetine on the density of GTP-binding-proteins in platelet membrane in patients with major depressive disorder.

Song Y, Zhou D, Fan J, Luo H, Halbreich U.

J Affect Disord. 2007 Mar;98(3):253-7. Epub 2006 Aug 17.

PMID:
16919758
2.

A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial.

Goodyer IM, Dubicka B, Wilkinson P, Kelvin R, Roberts C, Byford S, Breen S, Ford C, Barrett B, Leech A, Rothwell J, White L, Harrington R.

Health Technol Assess. 2008 May;12(14):iii-iv, ix-60.

3.

Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment.

Song C, Halbreich U, Han C, Leonard BE, Luo H.

Pharmacopsychiatry. 2009 Sep;42(5):182-8. doi: 10.1055/s-0029-1202263. Epub 2009 Sep 1.

PMID:
19724980
4.

The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes.

March JS, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J.

Arch Gen Psychiatry. 2007 Oct;64(10):1132-43. Erratum in: Arch Gen Psychiatry. 2008 Jan;65(1):101.

PMID:
17909125
5.

Short-term psychodynamic psychotherapy and fluoxetine in major depressive disorder: a randomized comparative study.

Salminen JK, Karlsson H, Hietala J, Kajander J, Aalto S, Markkula J, Rasi-Hakala H, Toikka T.

Psychother Psychosom. 2008;77(6):351-7. doi: 10.1159/000151388. Epub 2008 Aug 14.

PMID:
18701831
6.

Time to rehospitalization in patients with major depressive disorder taking venlafaxine or fluoxetine.

Lin CH, Lin KS, Lin CY, Chen MC, Lane HY.

J Clin Psychiatry. 2008 Jan;69(1):54-9.

PMID:
18312038
7.

Lipid peroxidation and antioxidant protection in patients during acute depressive episodes and in remission after fluoxetine treatment.

Gałecki P, Szemraj J, Bieńkiewicz M, Florkowski A, Gałecka E.

Pharmacol Rep. 2009 May-Jun;61(3):436-47.

8.

Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression.

Krystal A, Fava M, Rubens R, Wessel T, Caron J, Wilson P, Roth T, McCall WV.

J Clin Sleep Med. 2007 Feb 15;3(1):48-55.

PMID:
17557453
9.

Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial.

Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, Mohebbi-Rasa S, Raznahan M, Kamalipour A.

Depress Anxiety. 2009;26(7):607-11. doi: 10.1002/da.20589.

PMID:
19496103
10.

The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks.

March J, Silva S, Vitiello B; TADS Team.

J Am Acad Child Adolesc Psychiatry. 2006 Dec;45(12):1393-403.

PMID:
17135984
11.
12.

Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS).

Kennard B, Silva S, Vitiello B, Curry J, Kratochvil C, Simons A, Hughes J, Feeny N, Weller E, Sweeney M, Reinecke M, Pathak S, Ginsburg G, Emslie G, March J; TADS Team.

J Am Acad Child Adolesc Psychiatry. 2006 Dec;45(12):1404-11.

PMID:
17135985
13.

Effect of folic acid combined with fluoxetine in patients with major depression on plasma homocysteine and vitamin B12, and serotonin levels in lymphocytes.

Resler G, Lavie R, Campos J, Mata S, Urbina M, García A, Apitz R, Lima L.

Neuroimmunomodulation. 2008;15(3):145-52. doi: 10.1159/000151527. Epub 2008 Aug 21.

PMID:
18716414
14.

Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population.

Mao PX, Tang YL, Jiang F, Shu L, Gu X, Li M, Qian M, Ma C, Mitchell PB, Cai ZJ.

Depress Anxiety. 2008;25(1):46-54.

PMID:
17149753
15.

Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine.

Papakostas GI, Miller KK, Petersen T, Sklarsky KG, Hilliker SE, Klibanski A, Fava M.

J Clin Psychiatry. 2006 Jun;67(6):952-7.

PMID:
16848655
16.

Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder.

Papakostas GI, Petersen T, Sklarsky KG, Nierenberg AA, Alpert JE, Fava M.

Psychiatry Res. 2007 Jan 15;149(1-3):195-200. Epub 2006 Dec 8.

PMID:
17157390
17.

Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder.

Jazayeri S, Tehrani-Doost M, Keshavarz SA, Hosseini M, Djazayery A, Amini H, Jalali M, Peet M.

Aust N Z J Psychiatry. 2008 Mar;42(3):192-8. doi: 10.1080/00048670701827275.

PMID:
18247193
18.

Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS).

Vitiello B, Rohde P, Silva S, Wells K, Casat C, Waslick B, Simons A, Reinecke M, Weller E, Kratochvil C, Walkup J, Pathak S, Robins M, March J; TADS Team.

J Am Acad Child Adolesc Psychiatry. 2006 Dec;45(12):1419-26.

PMID:
17135987
19.

A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders.

Riggs PD, Mikulich-Gilbertson SK, Davies RD, Lohman M, Klein C, Stover SK.

Arch Pediatr Adolesc Med. 2007 Nov;161(11):1026-34.

PMID:
17984403
20.

Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS).

Curry J, Rohde P, Simons A, Silva S, Vitiello B, Kratochvil C, Reinecke M, Feeny N, Wells K, Pathak S, Weller E, Rosenberg D, Kennard B, Robins M, Ginsburg G, March J; TADS Team.

J Am Acad Child Adolesc Psychiatry. 2006 Dec;45(12):1427-39.

PMID:
17135988

Supplemental Content

Support Center